Ownership and insider activity for GT Biopharma, Inc. (GTBP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells.
Price
| Price | $7.81 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19000 | $576000 | $60000 | $28000 | $5.3M | $9.0M | $5.7M | $1.1M | $4.0M | $6.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $23.0M | $10.8M | $12.9M | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $21000 | $576000 | $90000 | $274000 | $5.7M | $32.2M | $16.6M | $14.1M | $4.2M | $8.1M |
| Property, Plant & Equipment | $4000 | $6000 | $35000 | $110000 | 0 | 0 | $165000 | $53000 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $253.8M | $25.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $25000 | $254.4M | $25.4M | $396000 | $5.7M | $32.2M | $16.7M | $14.1M | $4.2M | $8.1M |
| Accounts Payable | $2.1M | $2.5M | $1.8M | $1.9M | $2.2M | $8.2M | $3.1M | $4.3M | $3.9M | $748000 |
| Short-term Debt | $12.4M | $31000 | $10.8M | $13.2M | $26.3M | $31000 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $18.9M | $2.7M | $14.0M | $19.7M | $35.1M | $10.3M | $4.9M | $6.6M | $5.9M | $2.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $18.9M | $2.7M | $14.0M | $19.7M | $35.1M | $10.3M | $5.0M | $6.6M | $5.9M | $2.3M |
| Retained Earnings | -$124.6M | -$269.5M | -$528.7M | -$567.3M | -$595.6M | -$653.6M | -$674.5M | -$682.1M | -$695.2M | -$723.9M |
| Total Equity | -$18.8M | $251.9M | $11.5M | -$19.1M | -$29.3M | $21.9M | $11.7M | $7.5M | -$1.7M | $5.8M |
| Total Debt | $12.4M | $31000 | $10.8M | $13.4M | $26.3M | $31000 | $174000 | $58000 | 0 | 0 |
| Net Debt | $12.4M | -$545000 | $10.7M | $13.3M | $21.0M | -$31.9M | -$16.3M | -$13.9M | -$4.0M | -$6.8M |
| Working Capital | -$18.9M | -$2.1M | -$13.9M | -$19.4M | -$29.4M | $21.9M | $11.6M | $7.4M | -$1.7M | $5.8M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 2.61 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -128.11 |
Profitability
| Return on Equity | -443.08% |
| Return on Invested Capital | -457.75% |
| Return on Assets | -381.53% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTL · CARM · DRMA · LIPO · PBM · PTIX · REVB
Explore sector: Healthcare · Biotechnology
More sections of GTBP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks